Call scheduled for Wednesday, November 14 at 4:30pm Eastern Time
NEW YORK, Oct. 31, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC: AITB), a clinical-stage medical device
and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory
conditions including serious lung infections and pulmonary hypertension, today announced it will report financial results for its
fiscal second quarter ended September 30, 2018 after the market close on Wednesday, November 14, 2018 and will host a conference
call and webcast at 4:30pm Eastern Time.
| Conference Call &
Webcast |
|
| Wednesday, November 14th @ 4:30pm Eastern
Time |
| Domestic: |
800-949-2175 |
|
| International: |
323-994-2131 |
|
| Passcode: |
2733200 |
|
| Webcast: |
http://public.viavid.com/index.php?id=131848
|
| |
|
|
| Replays available through November
28th: |
| Domestic: |
844-512-2921 |
|
| International: |
412-317-6671 |
|
| Conference ID: |
2733200 |
|
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage medical device and biopharmaceutical company using nitric oxide (NO) to
treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract
infections that are not effectively addressed with current standards of care, as well as pulmonary hypertension, in various
settings. AIT is currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of
bronchiolitis and severe lung infections such as nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
CONTACT
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
Steve@AIT-Pharm.com
Bob Yedid
LifeSci Advisors, LLC
Bob@LifeSciAdvisors.com
(646) 597 6989
